sb 203580 has been researched along with icatibant in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (icatibant) | Trials (icatibant) | Recent Studies (post-2010) (icatibant) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 1,137 | 49 | 259 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooper, M; Ytrehus, K | 1 |
| Brunius, G; Domeij, H; Gustavsson, A; Yucel-Lindberg, T | 1 |
2 other study(ies) available for sb 203580 and icatibant
| Article | Year |
|---|---|
Cell survival signalling in heart derived myofibroblasts induced by preconditioning and bradykinin: the role of p38 MAP kinase.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Bradykinin; Bradykinin B2 Receptor Antagonists; Cell Hypoxia; Cell Survival; Enzyme Inhibitors; Fibroblasts; Glyburide; Imidazoles; Myocardium; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Rats; Receptor, Bradykinin B2; Signal Transduction; Sodium-Potassium-Exchanging ATPase | 2004 |
Bradykinin upregulates IL-8 production in human gingival fibroblasts stimulated by interleukin-1beta and tumor necrosis factor alpha.
Topics: Adolescent; Bradykinin; Bradykinin B2 Receptor Antagonists; Calcimycin; Cells, Cultured; Child; Fibroblasts; Gingiva; Humans; Imidazoles; Indoles; Interleukin-1; Interleukin-8; Ionophores; Kallidin; Maleimides; MAP Kinase Kinase 2; Protein Kinase C; Pyridines; Receptor, Bradykinin B2; Tumor Necrosis Factor-alpha; Up-Regulation | 2005 |